Clinical Trials Logo

Recurrent Ovarian Carcinoma clinical trials

View clinical trials related to Recurrent Ovarian Carcinoma.

Filter by:

NCT ID: NCT03508570 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Start date: May 15, 2018
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating participants with female reproductive cancer that has come back or is high grade and has spread extensively throughout the peritoneal cavity. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03456700 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Start date: March 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count.

NCT ID: NCT03428802 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Start date: March 8, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03412630 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Bevacizumab

Start date: February 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab. Computed tomography perfusion imaging monitors the effects of the drug treatment on the blood flow to the tumor, and may help to predict whether a certain drug therapy is likely be successful in a patient with ovarian, fallopian tube, or primary peritoneal cancer.

NCT ID: NCT03353831 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Start date: July 1, 2018
Phase: Phase 3
Study type: Interventional

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.

NCT ID: NCT03348631 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer

Start date: June 22, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tazemetostat works in treating patients with ovarian, primary peritoneal, or endometrial cancer that has come back. Drugs used in chemotherapy, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03325634 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer

Start date: December 5, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with ovarian or uterine cancer that has come back. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue.

NCT ID: NCT03277482 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Start date: February 6, 2018
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: - Durvalumab - Tremelimumab

NCT ID: NCT03206047 Suspended - Clinical trials for Recurrent Ovarian Carcinoma

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: September 22, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Monoclonal antibodies, such as atezolizumab, may block tumor growth in different ways by targeting certain cells. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

NCT ID: NCT03164980 Recruiting - Ovarian Cancer Clinical Trials

Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

COMPASS
Start date: November 27, 2017
Phase:
Study type: Observational

This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer. The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.